scholarly journals Serum Metabolomics for Biomarker Screening of Esophageal Squamous Cell Carcinoma and Esophageal Squamous Dysplasia Using Gas Chromatography-Mass Spectrometry

ACS Omega ◽  
2020 ◽  
Vol 5 (41) ◽  
pp. 26402-26412
Author(s):  
Su Zhang ◽  
Xin Lu ◽  
Chunxiu Hu ◽  
Yanli Li ◽  
Huan Yang ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Gas Chromatography ◽  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Gas Chromatography Mass Spectrometry ◽  
Chromatography Mass Spectrometry ◽  
Serum Metabolomics

PS02.161: METABOLIC MARKERS OF OESOPHAGEAL SQUAMOUS CELL CARCINOMA: A SYSTEMATIC REVIEW AND POOLED ANALYSIS

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 167-167
Author(s):  
Yan Mei Goh ◽  
Piers Boshier ◽  
Stefan Antonowicz ◽  
George Hanna
Keyword(s):  
Mass Spectrometry ◽  
Systematic Review ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Metabolic Pathways ◽  
Pooled Analysis ◽  
Oesophageal Squamous Cell Carcinoma ◽  
Chromatography Mass Spectrometry ◽  
Metabolic Biomarkers

Abstract Background Oesophageal squamous cell carcinoma (ESCC) is a major global health burden associated with poor survival. Patients suffering from this condition typically present at an advanced stage due to non-specific early symptoms. An increasing emphasis on early detection has led to the investigation of novel biomarkers of ESCC. This systematic review aims to define existing biomarkers of ESCC and to identify perturbations in associated metabolic pathways. Methods A systematic online literature search (1946–January 2018) was performed to identify studies reporting metabolic biomarkers of ESCC. Pooled point estimate of the hierarchal summary ROC curve of analysed metabolites was performed using bivariate meta-analyses. Conduct of this review was in accordance with the recommendations of the Cochrane Library and MOOSE guidelines. Results An online search identified 628 potential relevant studies, of which eight (including a total 508 patients) met inclusion criteria. All publications represented phase-I biomarker discovery studies. Methods used to assess metabolites in patients with ESCC included liquid chromatography-mass spectrometry (n = 6), gas chromatography-mass spectrometry (n = 1) and 1H-nuclear magnetic resonance (n = 1). Sample types utilised were plasma (n = 5), tissue (n = 2) and urine (n = 1). A total of 1670 metabolites were identified as being associated with ESCC. Key metabolic pathways involved included tricarboxylic acid cycle and in pathways of oxidative stress. Metabolites identified increased in ESCC are breakdown products of fatty acid synthesis and glycerophospholipid metabolism e.g.: palmitic acid, oleic acid, LysoPC(24:0), LysoPC(18:2), L-carnitine, branched chain amino acids e.g.: valine, leucine, isoleucine and phenylalanine. Metabolites decreased in ESCC are breakdown products of amino acid metabolism e.g: glutamine, carbohydrates e.g.: glucose and organic acids e.g.: α-ketoglutaric acid oxime. Pooled analysis of findings from five studies showed an area under the receiver-operating characteristic analysis curve of 0.96, sensitivity 88.0% (95% CI 80.8%-92.7%) and specificity 93.5% (95% CI 96.9%- 86.8%). Conclusion This is the first review to define metabolic biomarkers associated with ESCC. Significant variability in identified metabolites is evidence of the broad range of analytical techniques employed and the diversity of metabolic pathways associated with this disease. Notwithstanding, findings provide important insight in to those metabolites associated with ESCC and provide a basis for future studies. Disclosure All authors have declared no conflicts of interest.

scholarly journals Metabolomic Characterization Reveals ILF2 and ILF3 Affected Metabolic Adaptions in Esophageal Squamous Cell Carcinoma

2021 ◽  
Vol 8 ◽  
Author(s):  
Bin Zang ◽  
Wen Wang ◽  
Yiqian Wang ◽  
Pengfei Li ◽  
Tian Xia ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Acid Metabolism ◽  
Metabolic Reprogramming ◽  
Chain Acyl ◽  
Glycolysis Pathway ◽  
Cancer Tissues

Esophageal cancer (EC) is a common malignant disease in eastern countries. However, a study of the metabolomic characteristics associated with other biological factors in esophageal squamous cell carcinoma (ESCC) is limited. Interleukin enhancer binding factor 2 (ILF2) and ILF3, double-stranded RNA-binding proteins, have been reported to contribute to the occurrence and development of various types of malignancy. Nevertheless, the underlying functions of ILF2 and ILF3 in ESCC metabolic reprogramming have never been reported. This study aimed to contribute to the metabolic characterization of ESCC and to investigate the metabolomic alterations associated with ILF2 and ILF3 in ESCC tissues. Here, we identified 112 differential metabolites, which were mainly enriched in phosphatidylcholine biosynthesis, fatty acid metabolism, and amino acid metabolism pathways, based on liquid chromatography–mass spectrometry and capillary electrophoresis–mass spectrometry approaches using ESCC tissues and paired para-cancer tissues from twenty-eight ESCC patients. In addition, ILF2 and ILF3 expression were significantly elevated in EC tissues compared to the histologically normal samples, and closely associated with PI3K/AKT and MAPK signaling pathways in ESCC. Moreover, in ESCC tissues with a high ILF2 expression, several short-chain acyl-carnitines (C3:0, C4:0, and C5:0) related to the BCAA metabolic pathway and long-chain acyl-carnitines (C14:0, C16:0, C16:0-OH, and C18:0) involved in the oxidation of fatty acids were obviously upregulated. Additionally, a series of intermediate metabolites involved in the glycolysis pathway, including G6P/F6P, F1,6BP, DHAP, G3P, and 2,3BPG, were remarkably downregulated in highly ILF3-expressed ESCC tissues compared with the corresponding para-cancer tissues. Overall, these findings may provide evidence for the roles of ILF2 and ILF3 during the process of ESCC metabolic alterations, and new insights into the development of early diagnosis and treatment for ESCC. Further investigation is needed to clarify the underlying mechanism of ILF2 and ILF3 on acyl-carnitines and the glycolysis pathway, respectively.

scholarly journals Serum metabolomics analysis for the progression of esophageal squamous cell carcinoma

2021 ◽  
Vol 12 (11) ◽  
pp. 3190-3197
Author(s):  
Xia Li ◽  
Lihong Zhao ◽  
Mengke Wei ◽  
Jiali Lv ◽  
Yawen Sun ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Serum Metabolomics ◽  
Metabolomics Analysis
Sign in / Sign up

Export Citation Format

Share Document